A minimally invasive tool for predicting response to cancer treatment
We would like to invite you to participate in our partner company GeneTex's upcoming webinar on extracellular vesicles as a tool for predicting response to cancer treatment.
Webinar: Blood plasma-derived extracellular vesicles - A minimally invasive tool for predicting response to cancer treatment
Extracellular vesicles (EVs), including exosomes and microvesicles, are nanosized structures released in the extracellular space. EVs are released by many cell types, are present in all body fluids, and are involved in intercellular communications. EVs embody the status of the producer cells. Thus, they may serve as i) indicators of health or disease states, ii) minimally invasive biomarkers for disease diagnosis, or iii) predictors of therapeutic response. Despite the importance of EVs, current EV isolation methods have limitations. Dr. Okeoma's webinar will describe how her lab developed particle purification liquid chromatography (PPLC) as a superior EV isolation tool and applied it to discover that circulating blood plasma-derived EVs (BEVs) hold promise as minimally invasive biomarkers for predicting response to neoadjuvant chemotherapy in patients with breast cancer. Her findings have direct relevance to clinical management of breast cancer and likely other malignancies.
Speaker: Chioma M. Okeoma, Ph.D., Professor and Vice Chair of Research, Department of Pathology, Microbiology, and Immunology, School of Medicine at New York Medical College (NYMC) Valhalla, NY; Fellow of the Lovelace Biomedical Research Institute, Albuquerque, NM.
Date and Time: Tuesday, November 29, 2022 at 4:00 pm (CET)